Canada markets closed

ImmunoPrecise Antibodies Ltd. (IPA.V)

TSXV - TSXV Real Time Price. Currency in CAD
Add to watchlist
6.50+0.05 (+0.78%)
At close: 03:58PM EST
Currency in CAD

Valuation Measures4

Market Cap (intraday) 162.08M
Enterprise Value 143.96M
Trailing P/E N/A
Forward P/E N/A
PEG Ratio (5 yr expected) N/A
Price/Sales (ttm)7.04
Price/Book (mrq)2.45
Enterprise Value/Revenue 7.40
Enterprise Value/EBITDA -8.06

Trading Information

Stock Price History

Beta (5Y Monthly) 0.30
52-Week Change 3-13.33%
S&P500 52-Week Change 3-13.51%
52 Week High 38.81
52 Week Low 34.52
50-Day Moving Average 36.57
200-Day Moving Average 36.30

Share Statistics

Avg Vol (3 month) 315.04k
Avg Vol (10 day) 316.36k
Shares Outstanding 524.94M
Implied Shares Outstanding 6N/A
Float 820.82M
% Held by Insiders 11.06%
% Held by Institutions 15.72%
Shares Short (Nov 14, 2022) 416.31k
Short Ratio (Nov 14, 2022) 40.96
Short % of Float (Nov 14, 2022) 4N/A
Short % of Shares Outstanding (Nov 14, 2022) 40.07%
Shares Short (prior month Oct 13, 2022) 421.65k

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 30.00
Trailing Annual Dividend Yield 30.00%
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3Nov 22, 2020
Ex-Dividend Date 4N/A
Last Split Factor 21:5
Last Split Date 3Nov 22, 2020

Financial Highlights

Fiscal Year

Fiscal Year Ends Apr 29, 2022
Most Recent Quarter (mrq)Jul 30, 2022

Profitability

Profit Margin -117.44%
Operating Margin (ttm)-117.59%

Management Effectiveness

Return on Assets (ttm)-19.82%
Return on Equity (ttm)-37.57%

Income Statement

Revenue (ttm)19.46M
Revenue Per Share (ttm)0.92
Quarterly Revenue Growth (yoy)2.20%
Gross Profit (ttm)10.77M
EBITDA -20.52M
Net Income Avi to Common (ttm)-22.86M
Diluted EPS (ttm)-0.89
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)19.24M
Total Cash Per Share (mrq)0.77
Total Debt (mrq)1.12M
Total Debt/Equity (mrq)1.70
Current Ratio (mrq)5.06
Book Value Per Share (mrq)2.67

Cash Flow Statement

Operating Cash Flow (ttm)-19.27M
Levered Free Cash Flow (ttm)-9.95M